New acute treatments for headache

Neurological Sciences

Volumn 31, Issue SUPPL.1, 2010, Pages

  Rapoport, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute treatment of migraine; CGRP antagonist; DHE; Iontophoretic patch; Migraine therapy; Needle free injection; Oral inhalation; Sumatriptan

Indexed keywords

BIBN4096; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE MESILATE; GLUTAMIC ACID; OLCEGEPANT; PLACEBO; RIZATRIPTAN; SUBSTANCE P; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TELCAGEPANT; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; ZELRIX; ZOLMITRIPTAN; DICLOFENAC; DIPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; QUINAZOLINE DERIVATIVE; SEROTONIN AGONIST; VASOCONSTRICTOR AGENT;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; INHALER; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA AND VOMITING; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEPTOR BLOCKING; SKIN IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; HEADACHE AND FACIAL PAIN; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BOTULINUM TOXIN TYPE A; CLINICAL TRIALS AS TOPIC; DICLOFENAC; DIPEPTIDES; DRUG ADMINISTRATION ROUTES; HEADACHE DISORDERS; HUMANS; QUINAZOLINES; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 77955868216     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-010-0304-7     Document Type: Article

References (14)

1. Ramadan NM, Buchanan TM (2006) New and future migraine therapy. Pharmacol Ther 112:199-212 (Pubitemid 44301490)
2. Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56 (Pubitemid 23009909)
3. Levy D, Burstein R, Strassman AM (2005) Calcitonin gene related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698-705 (Pubitemid 41552545)
4. Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110 (Pubitemid 38298990)
5. Ho TW, Mannix LK, Fan X et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304-1312 (Pubitemid 351550355)
6. Ho TW, Ferrari MD, Dodick DW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2089-2090
7. Rapoport AM (2009) Antimigraine drugs: new frontiers. Neurol Sci 30(Suppl 1):S49-S54 (some of the above text is borrowed in entirety from Neurol Sci)
8. Pierce M, Marbury T, O'Neill C et al (2008) A novel patch formulation of sumatriptan succinate utilizing SmartReliefTM transdermal technology. Data presented at the 50th annual scientific meeting of the American Headache Society 28 June 2008
9. Armer T, Shrewsbury S, Newman S et al (2007) Aerosol delivery of ergotamine tartrate via a breath-synchronized plume-control inhaler in humans. Curr Med Res Opin 23:3177-3187
10. Shrewsbury S, Cook R, Taylor G et al (2008) Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) Inhaler. Headache 48:355-367 (Pubitemid 351517766)
11. Dodick DW, Mauskop A, Elkind AH et al (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache 45:315-324 (Pubitemid 40530195)
12. Mathew NT (2008) A double-blind comparison of botulinum toxin type A (BoNTA) and topiramate for the prophylactic treatment of transformed migraine headaches: A pilot study. Presented at the 12th congress of the European Federation of the European Societies: 23-26 Aug 2008, Madrid, Spain
13. Blumenfeld AM, Schim JD, Chippendale TJ (2008) Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 48:210-220 (Pubitemid 351178286)
14. Allergan announces positive top-line results from phase III BOTOX headache program-Released 11 Sept 2008 0900 a.m. Eastern Daylight Time